SCHEMBL16103646

SCHEMBL16103646

C[C@@H](OCc1ccccc1)[C@@H](N)CCC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.48
SLC1A2 P43004 2/20 0.48
SLC1A1 P43005 2/20 0.48
MEN1 O00255 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KMT2A Q03164 1/20 0.48
MMP9 P14780 2/20 0.45
MMP8 P22894 2/20 0.45
ALOX5 P09917 1/20 0.42
LTA4H P09960 2/20 0.40
RCE1 Q9Y256 1/20 0.40
ALDH1A1 P00352 1/20 0.40
SLC15A1 P46059 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16103223 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL10098470 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL10098457 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
Hydrochloric Acid SCHEMBL30169055 0.99 SLC1A3 (0.47) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL8514587 0.90 SLC1A3 (0.49) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL26205618 0.87 SLC1A3 (0.45) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
Hydrochloric Acid SCHEMBL22502605 0.85 EPHX1 (0.40) MEN1KMT2AMMP9MMP8ALOX5
Hydrochloric Acid SCHEMBL22502606 0.85 EPHX1 (0.40) MEN1KMT2AMMP9MMP8ALOX5
SCHEMBL22526197 0.85 S1PR2 (0.39)
SCHEMBL22525623 0.85 POLB (0.43) SLC1A3SLC1A2SLC1A1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
WO-2020206424-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed
US-8841257-B2 Inhibitors of STAT3 and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 SLC1A3 4757/4885SLC1A2 4748/4885SLC1A1 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.